Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: Rarecells | Rarecells, Inc. | Rarecells, Inc | Rarecells Inc. | Rarecells Inc | Rarecells Diagnostics | RARECELLS
Related tests:


Rarecells, Inc. announces a breakthrough publication on circulating giant cancer cells detected in patients with MDS (BioSpace)
"Rarecells...announce its breakthrough publication, written in partnership with the team of Dr. Azra Raza from Columbia University Irving Medical Center, revealing for the first time the presence of circulating giant cancer cells (CGCCs) in patients with Myelodysplastic Syndrome (MDS) at risk of developing acute myeloid leukemia (AML)."
Clinical data
Rarecells, Inc. announces successful series A funding, reaching $13 Million raised to develop liquid biopsy early cancer detection tests (Rarecells Press Release)
"Rarecells, Inc...announced...the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests."
Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of acute myeloid leukemia (AML) (Rarecells Press Release)
"Rarecells, Inc.,.announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET® -AML test for early detection of acute myeloid leukemia (AML) in patients with myelodysplastic syndrome (MDS)...The study, expected to begin in Q1 2022, will be the first clinical evaluation of the ISET® -AML test."
Financing • Licensing / partnership • New trial
ISET®-AML test